ClinicalTrials.gg
SuspendedNCT06589271Updated Apr 27, 2026

SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration

A Phase 1 interventional study of human umbilical cord mesenchymal stem cell suspension and total endoscopic extraction of lumbar nucleus pulposus in Lumbar Disc Degeneration, sponsored by Sclnow Biotechnology Co., Ltd.. Suspended at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Sclnow Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know · 3 judgments

Why this study was suspended
Lack of financial support

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Intervertebral Disc Degeneration with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Intervertebral Disc Degeneration · China.

Started
2026
the only one that year
Phase 1
Only one
of the 17
Registered
16th of 17
by date
Lead sponsor
1 of 17
Sclnow Biotechnology Co., Ltd.

Among the 17 studies in Intervertebral Disc Degeneration with a site in China, this one is the only one that started in 2026, is the only one in phase 1, and was the 16th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

3 of the 17 studies in Intervertebral Disc Degeneration with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Intervertebral Disc Degeneration with a site in China, or all of them as a file.
02

Study summary

In recent years, total endoscopic extraction of nucleus pulposus has been widely used in the treatment of lumbar disc herniation due to its advantages of less trauma, faster recovery and less cost. However, the residual nucleus pulposus may protrude again after extraction, and the stability of the operative segment decreases and the degeneration of the diseased segment accelerates. Therefore, while decompression of nerve root is completed under total endoscopic nucleus pulposus extraction, tissue engineering of nucleus pulposus is urgently needed to replace the lost part, repair the remaining nucleus pulposus, and enable the disc to be re-sealed and pressurized. Nucleus pulposus tissue engineering is mainly based on cell therapy, and the corresponding biological scaffolds are selected to transplant cells into the diseased area for treatment. However, the current nuclear tissue engineering has some shortcomings, such as limited seed cell source, difficult survival of seed cells, inflammatory rejection in the transplantation area, poor mechanical properties of biological scaffolds, poor degradation performance, and inability to produce biospecific reactions between materials and cells, which seriously restrict the clinical application of nuclear tissue engineering. Human umbilical cord mesenchymal stem cells (hUC-MSCs) are ideal seed cells for the treatment of lumbar disc herniation due to their wide availability, strong proliferation ability and good immune regulation. Therefore, in this project, hUC-MSCs are used for cell transplantation into the vertebral disc of diseased vertebrae. As the treatment method of this project is extremely minimally invasive, it is conducive to the widespread promotion of the technology.

Read the detailed description

In order to initially observe the safety and effectiveness of human umbilical cord mesenchymal stem cells (hUC-MSCs) transplantation in the treatment of lumbar disc degeneration, this project planned to include a single group of 20 patients with lumbar disc herniation, and adopt an open study design of non-random, self-controlled, single-dose group, and locally inject 2mL hUcMSCs into the lumbar disc of enrolled patients.

The patients were followed up 3, 6 and 12 months after injection to evaluate the safety of hUC-MSCs. Meanwhile, the improvement of patients' low back pain and quality of life were evaluated. Lumbar MRI is used to evaluate the improvement of patients' lumbar disc signal, proving that hUC-MSCs transplantation can delay lumbar disc degeneration and treat lumbar degenerative diseases.

03

Conditions studied

  • Lumbar Disc Degeneration
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-60 years old;
  2. The symptoms are lumbago combined with radiating pain of one lower limb;
  3. Failed conservative treatment for 3 months, including physical therapy, manual therapy and non-morphine drug therapy;
  4. CT/MRI clearly highlighted the nucleus pulposus pressing the nerve root and the location was consistent;
  5. Symptoms and imaging showed unilateral lumbar disc herniation;
  6. Imaging showed single-level lumbar disc herniation;
  7. MRI (T2WI) of Pfirrmann disc degeneration: Grade I-IV;
  8. Lumbar disc herniation segments: L3-4, L4-5, L5-S1;
  9. Unilateral full endoscopic extraction of nucleus pulposus;
  10. Sign the ;
  11. No previous history of spinal surgery.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of tumor and spinal infection;
  2. Patients with severe coagulation disorders, a history of drug abuse or taking oral anticoagulants;
  3. Coma or incapacitation;
  4. MRI (history of cardiovascular and cerebrovascular stent implantation, pacemaker, biostimulator, etc.);
  5. Pregnant women;
  6. Pregnancy or breastfeeding;
  7. Have participated in other clinical trials related to this project within the past 30 days;
  8. Those who have received stem cell therapy;
  9. Poor compliance, or can not correctly understand the cooperation so that it can not complete the interview;
  10. Received intervertebral disc interventional therapy within the past 3 months, such as radiofrequency, laser ablation, protease injection, Ozone injection;
  11. Highly allergic or have a history of severe allergies;
  12. Patients with severe disease or who are receiving therapy;
  13. Serious uncontrolled infection or high fever;
  14. Patients with shock, failure of vital organs and unstable vital signs;
  15. X-ray showed that the degree of stenosis of the diseased segment was more than 30% compared with the adjacent normal segment;
  16. Imaging showed lumbar disc herniation complicated with calcification;
  17. Imaging showed lumbar disc herniation with Modic Change;
  18. Imaging showed lumbar disc herniation complicated with severe spinal stenosis;
  19. Imaging showed lumbar disc herniation complicated with lumbar spondylolisthesis;
  20. Imaging showed lumbar disc herniation combined with spinal deformity;
  21. Mental disorders, cognitive disorders, or other physical diseases affecting the research results;
  22. Doctors believe that there are other reasons for not being included in the treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    hUC-MSCs transplantation group

    Human Umbilical Cord Mesenchymal Stem Cells

    Biological: human umbilical cord mesenchymal stem cell suspension

  • Active comparator
    control group

    suspension transplantation

    Procedure: total endoscopic extraction of lumbar nucleus pulposus

Interventions

  • Biologicalhuman umbilical cord mesenchymal stem cell suspension

    2 \* 10\^7 cells (2ml)

  • Proceduretotal endoscopic extraction of lumbar nucleus pulposus

    hUC-MSCs are injected into the opposite side of the minimally invasive surgical site immediately after surgery, and the puncture needle remains for 1 minute after injection and then pull out to prevent cell suspension leakage

06

What researchers measure

Primary outcomes

  1. Change of lumbar disc MRI (T2WI) signal values

    Lumbar MRI images are taken on day 0-1 (measured before stem cell transplantation), 3 months, 6 months and 12 months to record the signal value of the intervertebral disc (4 times in total) from level IV-V to level III and below.

    Time frame: 12 months

Secondary outcomes

  1. Lower back pain and lower extremity radiating pain relief

    VAS scores of low back pain and lower extremity radiative pain are recorded on day 0-1 (measured before stem cell transplantation), 3 months, 6 months, and 12 months (4 times in total) from score 4-10 to score 3 and below.

    Time frame: 12 months

  2. X-ray Disc Height Index (DHI)

    On day 0-1 (measured before stem cell transplantation), 3 months, 6 months, and 12 months, the patients take anterior and lateral lumbar X-rays and record the DHI value (4 times in total) to reach the outcome of DHI≤0.188.

    Time frame: 12 months

  3. MRI highlights changes in the size of the nucleus pulposus

    On day 0-1 (measured before stem cell transplantation), 3 months, 6 months and 12 months, lumbar MRI is taken to measure the size of the protruded nucleus pulposus and record (4 times in total) to reach the outcome of size between 0.7cm×0.5cm×0.5cm and 2.4cm×2.0cm×1.5cm.

    Time frame: 12 months

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, 200080, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Sep 19, 2024
StartEst.
Dec 31, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06589271
Lead sponsor
Sclnow Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Dec 31, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion